These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35236333)

  • 1. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
    Krens SD; van Erp NP; Groenland SL; Moes DJAR; Mulder SF; Desar IME; van der Hulle T; Steeghs N; van Herpen CML
    BMC Cancer; 2022 Mar; 22(1):228. PubMed ID: 35236333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.
    Krens SD; van Boxtel W; Uijen MJM; Jansman FGA; Desar IME; Mulder SF; van Herpen CML; van Erp NP
    Int J Cancer; 2022 Jan; 150(2):308-316. PubMed ID: 34494665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
    J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
    Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
    Clin Genitourin Cancer; 2024 Jun; 22(3):102060. PubMed ID: 38521648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens.
    Tan Z; Völler S; Yin A; Rieborn A; Gelderblom AJ; van der Hulle T; Knibbe CAJ; Moes DJAR
    Clin Pharmacokinet; 2024 Jun; 63(6):857-869. PubMed ID: 38874883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
    Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
    Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
    Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
    Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
    Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
    Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
    Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
    Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
    Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
    Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
    Blanchet B; Xu-Vuilard A; Jouinot A; Puisset F; Combarel D; Huillard O; Le Louedec F; Thomas F; Teixeira M; Flippot R; Mourey L; Albiges L; Pudlarz T; Joly C; Tournigand C; Chauvin J; Puszkiel A; Chatelut E; Decleves X; Vidal M; Goldwasser F; Oudard S; Medioni J; Vano YA
    Br J Cancer; 2024 Apr; 130(6):961-969. PubMed ID: 38272963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
    Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
    Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
    Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
    Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
    Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
    Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.